Please use this identifier to cite or link to this item: https://www.um.edu.mt/library/oar/handle/123456789/11236
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBaldacchino, Ian
dc.contributor.authorBezzina, Sarah
dc.contributor.authorBalzan, Daniela
dc.contributor.authorBalzan, Gabriella
dc.contributor.authorDebattista, Daniel
dc.contributor.authorCalvagna, Victor
dc.date.accessioned2016-07-08T07:34:05Z
dc.date.available2016-07-08T07:34:05Z
dc.date.issued2016
dc.identifier.citationMalta Medical Journal. 2016, Vol. 28(2), p. 3-8en_GB
dc.identifier.urihttps://www.um.edu.mt/library/oar//handle/123456789/11236
dc.description.abstractIntroduction: Consumption of blood products is significant aiming to treat low cell counts and improve quality of life however 9% to 44% of the total consumption in centres abroad are unjustified. We reviewed thresholds at which blood products were administered and costs incurred by administering blood products at the local paediatric oncology ward at Mater Dei hospital and assessed whether they were inkeeping with local guidelines. Methods: Patient files were analyzed retrospectively for demographics, disease, type and amount of blood products used from January to May 2013. The costs involved were obtained from the Blood Bank at Mater Dei Hospital. The standards used were the protocol by HBB regarding administration on KURA and ‘Supportive care protocols’ in paediatric oncology and haematology. Results: Nine children were given blood products. Red cell products (RCP) use ranged from 0-10 units. and platelets derived products ranged 0- 12 units per patient. haemoglobin levels and platelet counts before transfusions ranged from 3.1 to 8.6g/dL and 9 to 60x109/L respectively. The total cost for the department was €17,950 while the total amount spent for tests done prior to ordering products was €3,276 out of 22 RCP requests for transfusion only once were RCPs transfused above the standard 7g/dL. Platelets were requested 26 times. Documentation regarding the reason for administration was lacking in patient files. Conclusion: The use of blood products is dependent on patient needs and is not influenced by prices. Thresholds at which platelets and RCP are administered vary according to the clinical scenario. Rising costs and shrinking donor pools require blood products to be used judiciously.en_GB
dc.language.isoenen_GB
dc.publisherMalta Medical Journalen_GB
dc.rightsinfo:eu-repo/semantics/openAccessen_GB
dc.subjectBlood banks -- Cost effectivenessen_GB
dc.subjectBlood banks -- Economic aspectsen_GB
dc.subjectCancer in children -- Malta -- Case studiesen_GB
dc.titleThe cost of blood in paediatric oncology patientsen_GB
dc.typearticleen_GB
dc.rights.holderThe copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holder.en_GB
dc.description.reviewedpeer-revieweden_GB
Appears in Collections:MMJ, Volume 28, Issue 2
MMJ, Volume 28, Issue 2

Files in This Item:
File Description SizeFormat 
The cost of blood in paediatric oncology patients.pdf913.92 kBAdobe PDFView/Open


Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.